Suppr超能文献

紫杉醇、卡铂和吉西他滨作为根治性膀胱切除术后复发的伴腺性分化的膀胱尿路上皮癌二线化疗的成功治疗:一例报告

Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report.

作者信息

Fukuhara Hiroki, Kakizaki Hiroshi, Kaneko Hisashi, Yamanobe Takuya, Ushijima Masaki, Kuboki Yuya, Tsuchiya Norihiko

机构信息

Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata City, Yamagata Prefecture, 998-9585, Japan.

Department of Urology, Nihonkai General Hospital, 30 Akiho-cho, Sakata City, Yamagata Prefecture, 998-8501, Japan.

出版信息

Urol Case Rep. 2017 Sep 8;15:11-13. doi: 10.1016/j.eucr.2017.08.001. eCollection 2017 Nov.

Abstract

Urothelial carcinoma of the bladder (UCB) with glandular differentiation is a histological variant (HV) that is more likely to have positive extravesical tumors or nodes than those in pure UCB. Cisplatin-based neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) is more effective for pure UCB; however, few reports are available on second-line chemotherapy for recurrence of UCB with HV. Here we report a 65-year-old Japanese male diagnosed with local recurrence UCB with HV after NAC + RC who safely achieved complete response with paclitaxel, carboplatin, and gemcitabine combination chemotherapy.

摘要

膀胱尿路上皮癌(UCB)伴腺性分化是一种组织学变体(HV),与单纯UCB相比,其更有可能出现膀胱外肿瘤或淋巴结阳性。根治性膀胱切除术(RC)前基于顺铂的新辅助化疗(NAC)对单纯UCB更有效;然而,关于HV型UCB复发的二线化疗的报道很少。在此,我们报告一名65岁的日本男性,在接受NAC + RC后被诊断为HV型UCB局部复发,其通过紫杉醇、卡铂和吉西他滨联合化疗安全地实现了完全缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e8/5595231/cc14e18cf767/gr1.jpg

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验